ASH 2021 | Using ctDNA assays to monitor clonal evolution in FL
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, reports on an ongoing prospective study that aims to investigate clonal evolution in tumor DNA and how this affects disease progression in patients with follicular lymphoma (FL). Dr Roschewski discusses the variation in treatment requirements seen in patients with FL, and then explains the aim of this ongoing clinical trial (NCT03190928). Following this, Dr Roschewski draws focus on the use of a circulating tumor DNA (ctDNA) assay in this trial and compares the findings from this assay to other traditional tumor monitoring methods, such as PET scans. To conclude, Dr Roschewski explains some factors that were observed with the ctDNA assay, including total metabolic tumor burden, how these factors change over time, and the implications that these findings have for future studies in FL. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
